首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   340篇
  免费   25篇
  国内免费   1篇
儿科学   18篇
妇产科学   3篇
基础医学   81篇
口腔科学   3篇
临床医学   24篇
内科学   87篇
皮肤病学   2篇
神经病学   25篇
特种医学   6篇
外科学   20篇
综合类   4篇
预防医学   11篇
眼科学   12篇
药学   50篇
中国医学   2篇
肿瘤学   18篇
  2023年   2篇
  2022年   7篇
  2021年   10篇
  2020年   8篇
  2019年   9篇
  2018年   13篇
  2017年   13篇
  2016年   9篇
  2015年   15篇
  2014年   18篇
  2013年   16篇
  2012年   29篇
  2011年   33篇
  2010年   13篇
  2009年   11篇
  2008年   20篇
  2007年   24篇
  2006年   16篇
  2005年   13篇
  2004年   10篇
  2003年   17篇
  2002年   15篇
  2001年   3篇
  2000年   3篇
  1999年   6篇
  1998年   2篇
  1997年   1篇
  1996年   3篇
  1995年   1篇
  1993年   2篇
  1992年   4篇
  1991年   3篇
  1990年   3篇
  1989年   2篇
  1988年   2篇
  1987年   1篇
  1986年   1篇
  1985年   2篇
  1983年   1篇
  1980年   1篇
  1976年   2篇
  1974年   1篇
  1973年   1篇
排序方式: 共有366条查询结果,搜索用时 0 毫秒
361.
362.

Background

Young fit patients with mantle cell lymphoma (MCL) are commonly treated with induction chemotherapy followed by high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT). Induction regimens with modifications of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and/or incorporation of high-dose cytarabine (HDAC) appear more effective than R-CHOP alone.

Patients and Methods

We adopted a modification of the Nordic protocol using standard, rather than higher dose R-CHOP, alternating with HDAC (rituximab plus HDAC), for 3 cycles each or, for patients already treated with R-CHOP alone before referral for AHCT, an additional 2 cycles of rituximab plus HDAC. We herein report our experience with 28 patients treated with this regimen who proceeded to AHCT, and compare their outcomes with patients treated with either standard-dose R-CHOP (n = 38) or R-HCVAD/MA (cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with methotrexate, and cytarabine; n = 21), before AHCT.

Results

With a median follow-up duration of 26 months, our data show that this modification of the Nordic regimen is a highly effective pre-AHCT first-line therapy for MCL (3-year progression-free and overall survival rates of 69% and 75%, respectively).

Conclusion

By using a less intense induction, this regimen can serve as a platform for combined use of novel agents, with less risk of additive toxicity.  相似文献   
363.
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia. An imbalance of different neurotransmitters--glutamate, acetylcholine, dopamine, and serotonin--has been proposed as the neurobiological basis of behavioral symptoms in AD. The molecular changes associated with neurotransmission imbalance in AD are not clear. We hypothesized that altered reuptake of neurotransmitters by vesicular glutamate transporters (VGLUTs), excitatory amino acid transporters (EAATs), the vesicular acetylcholine transporter (VAChT), the serotonin reuptake transporter (SERT), or the dopamine reuptake transporter (DAT) are involved in the neurotransmission imbalance in AD. We tested this hypothesis by examining protein and mRNA levels of these transporters in postmortem prefrontal cortex from 10 AD patients and 10 matched non-AD controls. Compared with controls, protein and mRNA levels of VGLUTs, EAAT1-3, VAChT, and SERT were reduced significantly in AD. Expression of DAT and catechol O-methyltransferase was unchanged. Reduced VGLUTs and EAATs may contribute to an alteration in glutamatergic recycling, and reduced SERT could exacerbate depressive symptoms in AD. The reduced VAChT expression could contribute to the recognized cholinergic deficit in AD. Altered neurotransmitter transporters could contribute to the pathophysiology of AD and are potential targets for therapy.  相似文献   
364.
365.
366.
Cardiac masses pose diagnostic challenges. We present a 62‐year‐old woman presented for evaluation of chest pain and palpitations. Transthoracic echocardiography showed left atrial mass, which was subsequently identified as hiatal hernia by cardiac magnetic resonance imaging.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号